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Abstract
Background The early life environment may influence susceptibility to obesity and metabolic disease in later life through
epigenetic processes. SLC6A4 is an important mediator of serotonin bioavailability, and has a key role in energy balance.
We tested the hypothesis that methylation of the SLC6A4 gene predicts adiposity across the life course.
Methods DNA methylation at 5 CpGs within the SLC6A4 gene identified from a previous methyl binding domain array was
measured by pyrosequencing. We measured DNA methylation in umbilical cord (UC) from children in the Southampton
Women’s Survey cohort (n= 680), in peripheral blood from adolescents in the Western Australian Pregnancy Cohort Study
(n= 812), and in adipose tissue from lean and obese adults from the UK BIOCLAIMS cohort (n= 81). Real-time PCR was
performed to assess whether there were corresponding alterations in gene expression in the adipose tissue.
Results Lower UC methylation of CpG5 was associated with higher total fat mass at 4 years (p= 0.031), total fat mass at 6–
7 years (p= 0.0001) and % fat mass at 6–7 years (p= 0.004). Lower UC methylation of CpG5 was also associated with
higher triceps skinfold thickness at birth (p= 0.013), 6 months (p= 0.038), 12 months (p= 0.062), 2 years (p= 0.0003), 3
years (p= 0.00004) and 6–7 years (p= 0.013). Higher maternal pregnancy weight gain (p= 0.046) and lower parity (p=
0.029) were both associated with lower SLC6A4 CpG5 methylation. In adolescents, lower methylation of CpG5 in per-
ipheral blood was associated with greater concurrent measures of adiposity including BMI (p ≤ 0.001), waist circumference
(p= 0.011), subcutaneous fat (p ≤ 0.001) and subscapular, abdominal and suprailiac skinfold thicknesses (p= 0.002, p=
0.008, p= 0.004, respectively). In adipose tissue, methylation of both SLC6A4 CpG5 (p= 0.019) and expression of SLC6A4
(p= 0.008) was lower in obese compared with lean adults.
Conclusions These data suggest that altered methylation of CpG loci within SLC6A4 may provide a robust marker of
adiposity across the life course.
Introduction
Obesity is a disorder of energy balance resulting from a
combination of genetic, lifestyle and environmental fac-
tors, and is a major risk factor for non-communicable
diseases including type-2 diabetes and cardiovascular
disease. Polymorphisms in several genes have been linked
to obesity [1–3], but to date genetic variation only
accounts for a modest proportion (<10%) of obesity risk at
the population level [4, 5]. Epidemiological and experi-
mental studies suggest that susceptibility to adiposity and
metabolic disease in later life is influenced by the early
life environment [6]. In animal studies, variation in
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maternal body composition and diet leads to alterations in
metabolism and body composition in the offspring [7],
while in humans maternal obesity and excess gestational
weight gain independently increase adiposity and risk of
obesity in the infant, child and adult [8]. The mechanisms
underlying these relationships are poorly understood, but
modulation of the epigenome, in particular DNA methy-
lation, is thought to be a key mechanism.
Epigenetic processes, which include DNA methylation,
histone modifications and non-coding RNAs, induce
heritable changes in gene expression without altering the
gene sequence. In animal models, variations in the
maternal diet induces epigenetic changes in a range of
metabolic control genes, this is accompanied by changes
in gene expression and metabolism in the offspring [9–
11]. Human studies have also suggested an important role
for epigenetic processes in mediating the effects of early
life environment. For example, methylation of a CpG
within the promoter of RXRA in umbilical cord predicted
>25% of the variation in percent and absolute fat mass in
children aged 9 years, with replication being found in a
second independent cohort of 6 year old children [12]. In
a separate study, methylation of specific CpG loci in the
promoter of PGC1α at 5–7 years of age predicted adip-
osity year-on-year from 8 to 14 years [13]. These findings
support the hypothesis that epigenetic marks induced
during development make an important contribution to
phenotype and suggest that detection of such marks in
peripheral tissues may provide predictive markers of later
phenotype.
To identify further epigenetic marks at birth associated
with later adiposity, we previously carried out a dis-
covery scan of DNA methylation in the promoters of all
refseq genes in umbilical cord DNA using a methyl
capture array (MBD-array). We aimed to identify
methylation differences in umbilical cord DNA at birth
associated with percentage fat mass in children aged 6
years. Our analyses identified 93 differentially methy-
lated regions (DMRs) [14], including a DMR within the
first intron of the SLC6A4 gene, which encodes the ser-
otonin transporter. SLC6A4 has a major role in mod-
ulating the bioavailability of the neurotransmitter
serotonin [15], which is synthesised both peripherally
and in the central nervous system (CNS), and has a key
role in modulating mood, anxiety, and energy homo-
eostasis [16, 17]. Polymorphisms within SLC6A4 have
been associated with obesity in children [18] and adults
[19], while differential methylation of the promoter
region of SLC6A4 in peripheral blood has been asso-
ciated with concurrent obesity in adults [20].
Given the central role that SLC6A4 has in energy
homoeostasis, and the previous genetic and epigenetic
associations with obesity, this study sought to examine the
relationship between SLC6A4 DMR methylation in cord
tissue at birth and adiposity in infancy and childhood in
children from the Southampton Women’s Survey (SWS)
cohort (n= 680). Here, we report an association between
the methylation of CpG loci within the SLC6A4 gene at
birth and measures of adiposity from birth through to 6
years of age. To assess whether this effect is sustained
through the life course, we additionally measured SLC6A4
DMR methylation in peripheral blood mononuclear cells
(PMBCs) from adolescents aged 17 years in the RAINE
study and in subcutaneous adipose tissue in lean and obese
adults from the BIOCLAIMS cohort. We found that
SLC6A4 CpG methylation at Hg19 chr17:28561468 was
associated with adiposity in adolescents (n= 812) and in
adipose tissue from obese vs. lean adults (n= 81), sug-
gesting that altered methylation of CpG loci within
SLC6A4 may provide a robust marker of adiposity across
the life course.
Materials and methods
Southampton Women’s Survey (SWS) Cohort
The SWS is a prospective mother-offspring cohort study
that has assessed the diet, body composition, physical
activity and social circumstances of non-pregnant women
aged 20–34 years living in Southampton, UK. Compre-
hensive details of SWS have been published [21, 22].
Follow-up of the children and sample collection/analysis
was carried out under Institutional Review Board approval
(Southampton and South West Hampshire Research Ethics
Committee) with written informed consent. Offspring
adiposity was measured by dual-energy X-ray absorptio-
metry (DXA) at birth, 4 and 6–7 years of age and triceps
skinfold thickness at birth, 6 months, 1, 2, 3 and 6–7 years
of age. Table 1 shows cohort characteristics.
The West Australian Pregnancy Cohort (RAINE)
Study
The RAINE Study enroled pregnant women ≤ 18 weeks
gestation (1989–1991) through the antenatal clinic at King
Edward Memorial Hospital and nearby private clinics in
Perth, Western Australia. Detailed clinical assessments were
performed at birth (n= 2868) and the children followed up
at multiple time points including at 17 years of age, when a
blood sample was taken, and waist/hip circumference,
skinfold thickness and abdominal (subcutaneous and visc-
eral) adipose thickness measurements made [23]. The
Human Ethics Committees of King Edward Memorial
Hospital and Princess Margaret Hospital approved all pro-
tocols (Table 1). Informed, written consent to participate in
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the study was obtained from the mother of each child at
enrolment and at each subsequent follow-up.
BIOCLAIMS Cohort
The BIOCLAIMS study was a randomised controlled
clinical trial of male and female volunteers aged 18–65
years recruited in Southampton UK 2012–2013 (http://
bioclaims.uib.eu). The study was approved by the
National Research Ethics Service Committee South Cen-
tral Berkshire. Written informed consent was obtained
from all subjects. The study was registered at www.isrctn.
com as ISRCTN96712688. Subcutaneous adipose tissue
biopsies were collected from 81 volunteers at baseline
(lean n= 37, obese n= 44). Participants were grouped as
lean or obese according to their BMI: Lean participants
were determined as those with a BMI 18.5–25 kg/m2,
whilst obese participants had a BMI 30–40 kg/m2 with
waist circumference > 94 cm for men and >80 cm for
women (Table 1).
DNA extraction
For SWS offspring, genomic DNA was prepared by a high-
salt method from a 5 to 10 cm segment cut from the mid
portion of the umbilical cord [14]. Genomic DNA was
extracted from peripheral blood (RAINE cohort) using the
Puregene DNA isolation kit (Qiagen, Germany) and from
adipose tissue (BIOCLAIMS cohort) using the QIAamp
DNA mini kit (Qiagen, Germany).
Pyrosequencing
Bisulphite conversion and pyrosequencing reactions were
carried out [24] using primers listed in Table S1, which
were designed across the 5 CpG sites within the SLC6A4
DMR (TSS+ 1450 bp, Hg19 Chr:17(−) 28561505-
28561468) identified previously [14] (Fig. 1a). Summary
statistics for SLC6A4 methylation shown in Table S2. To
identify potential transcription factor binding sites across
the CpG sites within the SLC6A4 DMR Matinspector
analysis was carried out (omictools.com/matinspector-tool).
Genotyping analysis
Genotyping PCR reactions (Fig. 1b) on SWS and BIO-
CIAIMS participants used 50 ng genomic DNA extracted
from UC and adipose tissue, respectively (Table S1), and
were analysed using PyroMark MD 1.0 software (Biotage).
Genotyping of the RAINE participants used 250 ng DNA
on the Illumina Human 660-W Quad Array (San Diego,
CA) at the Centre for Applied Genomics (Toronto, Canada).
Additional imputation using Mach 1.0.18.c [25] for pre-
phasing and MiniMac [26] for imputation against reference
panel 1000G Phase3 data. A total of 97,718 SNPs were
removed at genotyping QC due to a call rate < 0.95%, 919
SNPs were removed due to Hardy–Weinberg equilibrium
< 5.7 × 10E−7, and 35,502 SNP with a MAF < 0.05 were
removed.
RT-PCR
Adipose tissue was processed using the RNeasy Lipid
Tissue kit (Qiagen, Germany) according to manufacturer’s
instructions. A total of 500 ng RNA was incubated with 10
µM random nonamers, 0.5 µM dNTP’s and 200 U M-MLV
RT, followed by cDNA amplification using the QuantiTect
SLC6A4 primers (Qiagen, Germany).
Statistical methods
Statistical analysis was carried out using Stata (Statacorp)
versions 13.1/14.0/14.2. Distributions were examined prior to
analysis, and post analysis diagnostic checks were performed
where necessary to ensure assumptions were not violated. All
outcome and predictor variables were standardised to a mean
of zero and standard deviation (SD) of one, for ease of
interpretation. Adiposity was measured as % fat and total fat,
and methylation was measured as % methylation, with
regression coefficients (β) representing the SD change in %
fat (or total fat) for each SD change in methylation (Table S2).
The skinfold thickness measurements used at each age were
calculated using the mean of three skinfold measures, with
regression coefficients (β) representing the standard deviation
A 
AGCAAATATTTAATGTGTTTTGCCTTCAGTTACATAGGAAAAATGTCTAAGAAGGTGACA 
CpG1 
TTGGGACTTGTGTTTAATGAAACAGAGAACTGTGGGCAGCGTCAGTGTTGGGTTTTTAGG 
CpG2 
AGCRTAGGGAGCACACAGCTTTGACTCTTTGTCCCATTACTTGCTTCTGTGTGAAGCCAC 
rs141303113 
CpG3 CpG4 CpG5
TGAGGCCCCAGSGTTCGGGTTTTCCTGCCAYGCACTCTGGGGTGGCAGTGACCGTTCCAA 
                  rs56377481                           rs56105746 
YATGGWTGAGTGAGAAGCAGGTTCTTATGAGGTTTGTGCAAATTGAGCAAGCCACTTGGG 
rs2020934 rs2020935 
GCATGGGTTTTTCCTCTTTTCTTTCTTTCTTTCTTTTTCCCACTAAAGAACAGATTGAAA 
B 
Fig. 1 Location of the SLC6A4 DMR. Location of the SLC6A4 DMR
and known genetic variants is shown in relation to the SLC6A4 gene. a
The location of the SLC6A4 DMR (GRCh37/hg19
Chr17:2856138128561680negative strand) is shown in relation to the
first exon of SLC6A4. b The location of the CpG’s measured by
pyrosequencing and nearby characterised genetic variants is shown.
The DMR is shown in grey (reverse strand Chr17:28561381-
28561680). The underlined region indicates the region sequenced by
Pyrosequencing (either SNP or methylation assay)
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change in skinfold thickness for each SD change in methy-
lation. Where appropriate, measures of adiposity and skinfold
thickness were transformed to satisfy the assumption of nor-
mality. Regression models were built using child’s fat mass,
% fat mass or skinfold thickness as outcomes, and CpG
methylation as the predictor. All results are presented as
regression coefficients (β) with their associated p-values and
95% confidence intervals. Statistical comparisons of gene
expression, or CpG methylation with the lean and obese
groups from the BIOCLAIMS cohort was by logistic
regression. Analyses were adjusted for sex, and for age where
appropriate.
Two of the SLC6A4 SNPs (rs2020934 and rs2020935)
were analysed to assess their impact on results. Where
possible, both additive and co-dominant models were
considered. Mann–Whitney/Kruskal–Wallis tests were
performed on CpG 1-5 for rs2020934 and rs2020935,
respectively. DXA total fat (at birth, 4 and 6 years of
age) was the outcome used as the primary measure of
child’s fat mass across all ages in the following regres-
sions; our regression models were adjusted (i) for SNPs
individually and (ii) for both rs2020934 and rs2020935
together.
Results
SWS cohort characteristics
Genomic DNA was extracted from the umbilical cord of
SWS infants (n= 680) who had measurements of adip-
osity using DXA or triceps skinfold thickness during
infancy and childhood. The infants had a median birth
weight of 3.48 kg and gestational age of 40.1 weeks; 50%
were female. Median maternal age at birth was 31.5 years,
pre-pregnancy median body mass index (BMI) 24.3 kg/m2
and pregnancy weight gain 0.35 kg/week; 48% were in
their first pregnancy and 12% smoked in late pregnancy.
Table 1 shows additional characteristics and median (5th–
95th percentile) cord tissue SLC6A4 methylation values
for CpGs 1-5.
Umbilical cord SLC6A4 CpG methylation and percent
and total fat mass in infancy/childhood
Examining the relationship between cord tissue SLC6A4
methylation at birth and infant/child adiposity, lower
CpG1 (Hg19:28561601) and CpG2 (Hg19:28561578)
methylation were associated with lower % fat mass age
6–7 years (CpG1, β= 0.118 (95% CI= 0.015, 0.221),
p= 0.025; CpG2, β= 0.091 (0.0001, 0.183), p= 0.05,
respectively) (Table 2), but were not associated with %
fat mass at birth or 4 years or with total fat mass at birth,
4 or 6–7 years. In contrast, lower CpG5
(Hg19:28561468) methylation was associated with
higher % fat mass at 6–7 years (β=−0.159 (−0.267,
−0.052), p= 0.004). Lower CpG5 methylation was also
associated with higher total fat mass at birth (β=−0.102
(−0.213, 0.009), p= 0.072), 4 years (β=−0.108
(−0.206, −0.010), p= 0.031) and 6–7 years (β=−0.219
(−0.325, −0.113), p= 0.0001) (Table 2, Fig. 2a). There
were no associations between the methylation of CpG3
(Hg19:28561505) or CpG4 (Hg19:28561490) and % or
total fat mass at any age.
Multivariate analysis of DXA % fat and total fat mass at
birth, 4 and 6 years of age adjusted for sex and age showed
that methylation of CpG5 was associated with total fat mass
at birth (β=−0.1261 (−0.250, −0.002), p= 0.046), 4
(β=−0.1104 (−0.215, −0.006), p= 0.039) and 6 years
(β=−0.2039 (−0.314, −0.094), p= 0.0003) of age and
with % fat mass (β=−0.1447 (−0.257, −0.033), p=
0.011) at 6 years; there was no association however
between CpG2 methylation and % or total fat mass at any
time point (Table S3). The effect size was such that for each
standard deviation increase in methylation of SLC6A4
CpG5, there was an average decrease of 0.219 standard
deviations in total fat mass at 6–7 years of age, accounting
for sex, age and batch effect. Additional adjustments for
smoking in pregnancy, parity, IOM pregnancy weight gain
and mother’s pre-pregnancy BMI did not substantially alter
the association between CpG5 methylation and total fat
mass at 4 and 6 years but did weaken the association with
total fat at birth (adjusted β= 0.0099 (−0.124,0.144), p=
0.884) and % fat mass at age 6 years (adjusted β=−0.0986
(−0.214,0.017), p= 0.0946).
Umbilical cord SLC6A4 methylation and triceps
skinfold thickness from birth to age 6–7 years
To determine whether cord SLC6A4 methylation was
associated with additional measures of adiposity in
childhood, we investigated the relationship between
SLC6A4 methylation and triceps skinfold thickness in the
SWS children from birth through to 6–7 years. Lower
methylation of CpG5 was associated with higher triceps
skinfold thickness at birth (β=−0.0993 (−0.177,
−0.021), p= 0.013,), 6 months (β=−0.090 (−0.174,
−0.005), p= 0.038,), 12 months (β=−0.0781 (−0.160,
0.004), p= 0.062), 2 years (β=−0.155 (−0.238,
−0.072), p= 0.0003), 3 years (β=−0.168, (−0.248,
−0.088), p= 0.00004) and 6 years (β=−0.104 (−0.186,
−0.022), p= 0.013) (Table S4, Fig. 2b). Tracking the
association of SLC6A4 CpG5 methylation with skinfold
thickness from birth to age 6–7 years, infants with the
lowest quarter of SLC6A4 methylation at birth had, on
average, the highest triceps skinfold thickness at each of
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the ages from birth to 6–7 years, while individuals with
the highest quarter of SLC6A4 methylation had, on aver-
age, the lowest skinfold thickness from birth to 6–7 years
(Fig. 2c). Lower CpG4 methylation was associated with
higher triceps skinfold thickness at birth (β=−0.137
(−0.254, −0.019), p= 0.023) but there were no associa-
tions at later ages. There were no associations between the
methylation of CpGs 1, 2 or 3 and triceps skinfold
thickness at any age.
Effects of genetic variation within the SLC6A4 DMR
on methylation of SLC6A4 DMCpGs in the SWS
cohort
Genotyping analysis in all participants excluded the pre-
sence of genetic variation within this sample set at the five
CpGs sites measured, including the known SNP sites
rs141303113 and rs56105746, which overlap with CpG2
and CpG4, respectively. SNPs rs56377481, rs2020934 and
Table 2 Associations between
umbilical cord SLC6A4CpG
methylation levels and child’s
fat mass in the SWS cohort
Phenotype CpG1
(standardised)
CpG2
(standardised)
CpG3
(standardised)
CpG4
(standardised)
CpG5
(standardised)
DXA: total fat at birth (standardised): adjusted for sex, age and
gestational age
n 301 294 302 299 299
β 0.063 −0.014 −0.099 −0.132 −0.102
p-value 0.341 0.837 0.086 0.136 0.072
95% CI (−0.067, 0.194) (−0.146, 0.118) (−0.212, 0.014) (−0.306, 0.042) (−0.213, 0.009)
DXA: %fat at birth (standardised): adjusted for sex, age and gestational age
n 301 294 302 299 299
β 0.079 −0.022 −0.084 −0.096 −0.075
p-value 0.232 0.74 0.141 0.271 0.177
95% CI (−0.051, 0.208) (−0.153, 0.109) (−0.195, 0.028) (−0.268, 0.075) (−0.185, 0.034)
DXA: total fat at 4 years (standardised): adjusted for sex
n 414 400 413 409 405
β −0.037 0.028 0.007 0.024 −0.108
p-value 0.498 0.558 0.89 0.75 0.031*
95% CI (−0.145, 0.071) (−0.065, 0.121) (−0.089, 0.102) (−0.123, 0.172) (−0.206, −0.010)
DXA: %fat at 4 years (standardised): adjusted for sex
n 414 400 413 409 405
β 0.01 0.011 −0.02 0.046 −0.081
p-value 0.854 0.814 0.682 0.536 0.104
95% CI (−0.098, 0.118) (−0.082, 0.104) (−0.115, 0.075) (−0.101, 0.194) (−0.179, 0.017)
DXA: total fat at 6 years (standardised): adjusted for sex and age
n 435 427 432 430 428
β 0.039 0.073 −0.028 −0.058 −0.219
p-value 0.451 0.112 0.575 0.438 0.0001**
95% CI (−0.063, 0.141) (−0.017, 0.164) (−0.126, 0.070) (−0.204, 0.089) (−0.325, −0.113)
DXA: %fat at 6 years (standardised): adjusted for sex and age
n 434 426 431 429 427
β 0.118 0.091 −0.024 −0.037 −0.159
p-value 0.025* 0.049* 0.628 0.621 0.004**
95% CI (0.015, 0.221) (0.0001, 0.183) (−0.123, 0.074) (−0.183, 0.110) (−0.267, −0.052)
Associations between %/total fat mass at birth, 4 and 6 years, adjusted for SLC6A4 batch effect. 95%
confidence limits (Cl) are shown
*p ≤ 0.01–0.05
**p ≤ 0.01
Bold values indicate a p value lower than 0.05
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Fig. 2 Lower methylation of SLC6A4 CpG5 is associated with
increased fat mass in the SWS and BIOCLAIMS cohorts. a Asso-
ciation between the methylation of SLC6A4 CpG5 total and % fat
mass at 6 years of age. Means are plotted for each individual. b
Associations between the methylation of SLC6A4 CpG5 at birth and
triceps skinfold thickness at birth, 6 months, 1, 2, 3 and 6 years of age.
Means are plotted for each individual. c Trajectory of triceps skinfold
thickness from 6 months to 6 years with respect to quarters of SLC6A4
CpG5 methylation. Values are age and sex adjusted (n= 244). Means
± SEM. d Adipose tissue SLC6A4 CpG5 methylation (n= 51) and
expression (n= 61) is shown for lean and obese individuals from the
BIOCLAIMS cohort. Whiskers show min to max. *p= 0.01–0.05,
**p ≤ 0.01
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rs2020935, which lie within the 300 bp SLC6A4 DMR were
also measured (Fig. 1b). Genotyping analysis excluded the
presence of variation at rs56377481 (Table S5), but the
influence of the higher frequency SNPs rs2020934 and
rs2020935 on SLC6A4 methylation was examined further
(Table S6). There were differences in methylation at CpG1
(p= 0.0004) and CpG3 (p= 0.005) with respect to geno-
type at rs2020934, and in the methylation at CpG4 (p=
0.034) and CpG5 (p= 0.024) with respect to genotype at
rs2020935. However, for both SNPs the median difference
in methylation measurements at CpG sites was <2%
(Table S7). The association between SLC6A4 CpG5
methylation and total fat mass remained after adjusting the
regression models for SNPs rs2020934 and rs2020935
(Table S8). Genotype alone was not significantly associated
with any of the adiposity outcomes measured (Table S9).
Maternal weight gain and parity is associated with
altered infant SLC6A4 methylation
To determine the potential maternal drivers of altered infant
SLC6A4 methylation, we examined the relationship
between SLC6A4 CpG5 methylation and maternal BMI,
gestational weight gain, parity, smoking and Vitamin D
status, five modifiable factors previously associated with
increased infant adiposity [27–32]. Higher maternal preg-
nancy weight gain and lower parity were both associated
with lower SLC6A4 CpG5 methylation (p= 0.046; p=
0.029, respectively). There were no associations with pre-
pregnancy maternal BMI, smoking or maternal vitamin D
status (Table 3).
SLC6A4 CpG5 methylation is associated with
adiposity in adolescents at 17 years of age from the
Raine Study
The methylation of SLC6A4 CpG5 was measured in DNA
from peripheral blood from adolescents aged 17 years from
the RAINE cohort (n= 1200) (Table 4). Adjusting for age
and sex, lower methylation of CpG5 was associated with
greater BMI (β=−0.167 (−0.246, −0.088), p ≤ 0.001)
waist circumference (β=−0.102 (−0.182, 0.0234), p=
0.011), subcutaneous fat (β=−0.136 (−0.216, −0.057),
p= 0.001), subscapular skinfold thickness (β=−0.123
(−0.2015, −0.045), p= 0.002), abdominal skinfold thick-
ness (β=−0.099 (−0.174, −0.025), p= 0.008), and
suprailiac skinfold thickness (β=−0.1096 (−0.185,
−0.034), p= 0.004) at age 17 years. Genotyping analysis
showed no significant effects of rs2020934 and rs2020935
on CpG5 methylation in the RAINE cohort (Table S6).
Blood cell counts were measured in these samples but
strong collinearity (Table S10) between blood cell counts
and BMI (variance inflation factors: 10.6–112.9) was
observed, increasing the variance of the regression coeffi-
cients and making them unstable (Table S11). It was
therefore not possible to adjust the association between
methylation and BMI for cell type.
Table 3 Associations between
maternal covariates and
umbilical cord SLC6A4CpG5
methylation levels in the SWS
cohort
Co-variate (continuous) n rs p-value
Mother’s pre-preg BMI (kg/m2) 626 −0.028 0.48
Pregnancy weight gain (continuous)(kg/week) 593 −0.082 0.046*
Co-variate (categorical) n Group Mean methylation (std error) p-value
Low vitamin D (<50 nmol/L) 230 <50 nmol/L 78.63 (0.38) 0.602
346 ≥50 nmol/L 79.19 (0.28)
Smoking during pregnancy 544 No 78.84 (0.24) 0.972
85 Yes 79.00 (0.66)
Parity 302 0 78.21 (0.36) 0.029*
329 1+ 79.47 (0.28)
Pregnancy weight gain (categorical) 131 Inadequate 79.78 (4.82) 0.063
186 Adequate 78.75 (5.95)
276 Excessive 78.36 (5.87)
Association between continuous maternal factors; Mother’s pre-preg BMI and Pregnancy weight gain and
SLC6A4 CpG5 methylation using Spearman correlations are shown. Associations between categorical
maternal factors: Low vitamin D (<50 nmol/L), Smoking during pregnancy and parity using ranksum test are
shown. Associations between categorical maternal factors: Pregnancy weight gain using Kruskal–Wallis test
is shown
EP early pregnancy, LP late pregnancy
*p ≤ 0.01–0.05
Bold values indicate a p value lower than 0.05
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Lower SLC6A4 methylation is associated with
obesity in adipose tissue from adults in the
BIOCLAIMS cohort
We next investigated whether SLC6A4 CpG5 was differ-
entially methylated in subcutaneous adipose tissue of obese
and lean adults from the BIOCLAIMS cohort (n= 65)
(Table 1). Controlling for age and sex, obese individuals
had lower SLC6A4 CpG5 methylation (p= 0.019) and
SLC6A4 mRNA expression (p= 0.008) in adipose tissue
compared to lean individuals (Fig. 2d, Table S12). Geno-
typing analysis in all participants excluded the presence of
SNPs at the cytosine of CpG5.
In silco analysis of putative transcription factor
binding sites across the DMR
CpG sites in close proximity are often co-regulated, how-
ever here, the CpG sites within the identified DMR of
SLC6A4 show different and opposite directions of asso-
ciations with measures of adiposity. We therefore carried
out in silco analysis of the SLC6A4 DMR to identify the
transcription factors that may bind across the CpGs of
interest and potentially lead to their differential regulation.
Matinspector analysis showed that the CpG sites of interest
lay within the binding sites of a number of transcription
factors, with CpG2 lying within a potential vitamin D-
Retinoid X receptor (VDR-RXR) response element and
CpG5 within a potential ZNF300 binding site (Table S13).
Discussion
Our findings show that lower DNA methylation in umbilical
cord and peripheral blood of a specific CpG site within the
SLC6A4 gene is associated with multiple measures of
adiposity in infancy, childhood and adolescence. Moreover,
in obese adults lower SLC6A4 methylation in adipose tissue
was accompanied by a change in SLC6A4 mRNA expres-
sion, suggesting that altered SLC6A4 methylation may be of
functional relevance in obesity.
The SLC6A4 gene encodes the serotonin transporter,
which has an important role in the regulation of emotion,
behaviour, energy balance and appetite control. Alterations
in SLC6A4 expression have been associated with food
intake and obesity in animals and humans; transgenic mice
overexpressing SLC6A4 are lighter and shorter than controls
[33], whereas SLC6A4 knockout mice develop late onset
obesity, hepatic steatosis, glucose intolerance, and insulin
resistance [34–36]. In humans, a promoter polymorphism
within the SLC6A4 gene results in the formation of either a
long or a short allele [37]. The short allele reduces tran-
scription compared to the long allele [38], and is associated
Table 4 Associations between peripheral blood SLC6A4 CpG5
methylation levels and measures of fat mass in children age 17
years from the RAINE cohort
Phenotype Standardised CpG5
BMI at 17 years; standardised;
adjusted for sex, age
n 843
β −0.167
p-value <0.001**
95% CI (−0.246, −0.088)
Waist circumference at 17 years;
standardised; adjusted for sex, age
n 813
β −0.102
p-value 0.011*
95% CI (−0.182, −0.0234)
Subcutaneous fat at 17 years;
standardised; adjusted for sex, age
n 774
β −0.136
p-value <0.001***
95% CI (−0.216, −0.057)
Visceral fat; standardised; adjusted
for sex, age
n 648
β 0.025
p-value 0.557
95% CI (−0.059, 0.111)
Subscapular skinfolds at 17 years;
standarised; adjusted for sex, age
n 785
β −0.123
p-value 0.002**
95% CI (−0.201, −0.045)
Abdominal skinfold at 17;
standardised; adjusted for sex, age
n 776
β −0.099
p-value 0.008**
95% CI (−0.174, −0.025)
Suprailiac skinfold at 17;
standardised; adjusted for sex, age
n 777
β −0.1096
p-value 0.004**
95% CI (−0.185, −0.034)
Associations between BMI, waist circumference, subcutaneous fat,
visceral fat and skinfold thickness age 17 years are shown. 95%
confidence limits (Cl) are shown
Ln natural logarithm
*p ≤ 0.01–0.05
**p ≤ 0.01, ***P ≤ 0.0001
Bold values indicate a p value lower than 0.05
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with obesity in children [18], adult males [19] and with type-
2 diabetes [38, 39]. Furthermore, in humans long-term use of
SSRI (selective serotonin reuptake inhibitors), is associated
with increased obesity and dyslipidaemia [40, 41].
Recent studies have suggested that serotonin has an
important role in regulating metabolism in peripheral tis-
sues. Serotonin receptors have been identified in virtually
all organs. Adipocytes express a functional system for ser-
otonin synthesis, reuptake and receptor activation, sug-
gesting that serotonin may directly regulate adipocyte
function [42]. Consistent with this, mice with a conditional
adipose-specific knockout of tryptophan hydroxylase 1, the
enzyme that catalyses the rate limiting step in serotonin
biosynthesis, exhibit increased energy expenditure, reduced
weight gain and decreased lipogenesis in white adipose
tissue, suggesting that adipocyte-derived serotonin is
important in energy homoeostasis [43].
In cord tissue from infants from the SWS cohort,
methylation of SLC6A4 CpG5 showed the strongest and
most consistent association with measures of adiposity from
birth through to 6 years of age. Two developmental path-
ways to obesity have been proposed; first, when foetal
undernutrition is followed by rapid weight gain, and sec-
ondly, when foetal overnutrition is linked to greater adip-
osity at birth and beyond [22, 27]. Our findings suggest that
lower SLC6A4 CpG5 methylation, associated with higher
adiposity from birth to 6–7 years, is a marker of the latter
pathway. Three of these results passed a strict Bonferroni
correction (p < 0.00083) in the SWS discovery cohort,
notwithstanding that Bonferroni is likely overly con-
servative as the different measures of adiposity were highly
correlated. Interestingly the associations between CpG5
methylation and total and % fat mass strengthened with age,
suggesting an altered response to exposure to risk factors of
obesity in later life, consistent with the paradigm of the
developmental programming of obesity. Understanding
how early life alters later life responses to an obesogenic
environment, potentially through alterations in energy
homoeostasis, appetite control or food choice will be critical
for the development of effective intervention strategies.
Weaker positive associations were also found between the
methylation of SLC6A4 CpGs 1 and 2 and % fat mass at 6–
7 years. Developmentally induced changes in methylation
are often CpG site specific [44], so this difference in the
strength and direction of the association observed between
the methylation of the CpG’s within the SLC6A4 DMR may
reflect different regulatory roles of the CpG sites within this
region. SLC6A4 CpGs 1 and CpG5 are 135 bp apart and
although CpG’s in close proximity are often co-regulated
and methylation levels correlated, this is not what is
observed for these sites. However, in silico analysis does
show that these CpG sites are located within the response
elements of different regulatory transcription factors,
suggesting that they may be differentially regulated
(Table S13).
In an independent cohort, lower methylation of SLC6A4
CpG5 in peripheral blood was associated with multiple
measures of adiposity at age 17 years, suggesting that
SLC6A4 methylation may be a robust marker of adiposity in
peripheral tissue types across a range of ages from infancy
to adolescence. Interestingly Zhou et al. [20] have reported
that higher SLC6A4 promoter methylation (−69 to –213
from the TSS) in peripheral blood leucocytes was associated
with obesity in an adult monozygotic twin study. In our
study using cord tissue, peripheral blood and adipose tissue,
methylation of CpG5, located 1450 bp downstream of the
TSS, was inversely associated with adiposity. This differ-
ence in the direction of the association between SLC6A4
methylation and adiposity between the two studies may
reflect the different location of the CpGs measured. Recent
studies have shown that promoter and gene body methyla-
tion are inversely related, with high promoter methylation
being associated with reduced transcription, and high gene
body methylation positively associated with transcription
[45]. Thus, the different direction of associations in the two
studies may both reflect a lower level of SLC6A4 tran-
scription associated with increased adiposity. Consistent
with this, we found lower SLC6A4 CpG5 methylation in
adipose tissue was accompanied by lower SLC6A4 mRNA
expression.
To date, the functional significance of altered SLC6A4
methylation in peripheral blood cells or cord tissue is not
known, although a number of studies have found that the
methylation status of CpGs in peripheral tissues such as
blood correlates with that of internal tissues [46, 47].
Interestingly, the methylation of specific CpGs in the pro-
moter of SLC6A4 in T cells and monocytes has been
associated with in vivo measures of brain serotonin synth-
esis [48]. In agreement with this, we showed that differ-
ential methylation of SLC6A4 in adipose tissue from a
separate population was also associated with obesity.
Although the downstream effects of reduced adipose tissue
SLC6A4 mRNA expression in our study are not known, this
change would suggest an increase in peripheral serotonin
availability in the obese state. Consistent with this,
increased serum serotonin levels have been associated with
obesity in mice [49].
The driving forces for the altered methylation of the
SLC6A4 DMR are currently unknown. Lower SLC6A4
methylation was, however, associated with both higher
maternal gestational weight gain and lower parity, maternal
factors previously linked to increased offspring adiposity
[28, 31]. Whether altered SLC6A4 methylation lies on a
causal pathway is not known. A substantial contribution to
variation in methylation levels between individuals can also
be a direct result of local genetic polymorphisms, so-called
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methylation quantitative trait loci (methQTL); the peak
enrichment for distance across cis methQTLs has been
experimentally determined as 45 bp [50]. In our study, the
SNPs rs2020934 and rs2020935 were statistically asso-
ciated with the methylation of several of the CpGs within
the DMR of SLC6A4, but effect sizes were small and did
not significantly affect the association between SLC6A4
CpG methylation and measures of adiposity.
Our study has several limitations. First, we analysed
DNA methylation in umbilical cord, blood and adipose
tissue, which represent different cell populations with dis-
tinct epigenetic profiles. We measured blood cellular het-
erogeneity in the RAINE cohort, but here the cellular
proportions strongly associated with measurements of
adiposity. There was a particularly strong association
between BMI and the peripheral blood neutrophil count,
and previous studies have also reported a linear relationship
between BMI and neutrophil number [51, 52]. Many studies
have also shown increased neutrophil activation in obese
subjects [53]. Multicolinearity was seen between all cell
types and BMI for CpG5, overinflating the standard errors
of the coefficients and making them unstable. Therefore
adjusting the association between methylation and BMI for
cellular proportions would violate the assumption of non-
colinearity, which is a prerequisite for regression analysis.
Consequently, we were unable to assess the dependence on
cellular heterogeneity of the association of SLC6A4
methylation in blood and BMI. We cannot rule out the
possibility that the association between SLC6A4 methyla-
tion in peripheral blood with adiposity in adolescence is
dependent upon differences in cellular composition in
blood. However, the existence of this association in dif-
ferent tissues, which are (in the case of adipose and cord)
more homogeneous in their cellular composition, suggests
that the relationship is not completely explained by cell
type. In any case, our data showing that methylation status
of SLC6A4 CpG5 can distinguish levels of adiposity across
a range of tissue types, suggests that altered methylation of
this CpG maybe a valuable prognostic biomarker to identify
individuals at risk and the efficacy of therapeutic interven-
tions, especially as such biomarkers are likely to be mea-
sured in DNA from whole tissue samples rather than
isolated specific cell types.
A second limitation of the study is that the number of
participants in the SWS cohort with DEXA measure-
ments at birth, 4 and 6 years and with sufficient DNA for
methylation analysis did not completely overlap, so there
are different numbers of participants at each time point.
Moreover, there was also a limited availability of tissues
in each cohort and in the SWS cohort, there were no
measures of maternal glycemia, which has been sug-
gested to be a driver of offspring epigenetic changes, so
we could not determine whether infant’s SLC6A4
methylation was associated with maternal dysglycemia.
Comparison of SLC6A4 methylation across tissue types
within the same individual would permit a greater
understanding of tissue-specific differences in DNA
methylation and the utility of SLC6A4 as a marker of
future obesity. Thirdly, we did not have longitudinal
methylation data, so we cannot ascertain whether
methylation of SLC6A4 changes during the life course or
identify the factors that modify its methylation. However,
this is the first study to define biomarkers of fat mass in
perinatal tissue and replicate this result in the adipose
tissue of adults from a separate cohort with associated
alterations in gene expression. Therefore, not only is this
epigenetic mark a potential biomarker of trajectory
towards obesity, but it is also possible that its altered
methylation may have functional consequences on energy
balance, making it a potential target for intervention
strategies to optimise health over the life course, or
possibly to reverse obesity.
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